Background: Clinical trials addressing the acneiform rash associated with epidermal growth factor receptor inhibitors are lacking.
Objective: We evaluated the ability of topical pimecrolimus to reduce the severity of cetuximab-related facial rash.
Methods: In all, 24 patients with metastatic colorectal cancer with cetuximab facial rash received twice daily pimecrolimus application for 5 weeks to half of the face. At baseline, week 2, and week 5, a dermatologist performed facial lesion counts, patients reported perceived severity of rash-related symptoms, and standardized facial photographs were obtained for blinded evaluation of global rash severity.
Results: Treatment sides had greater decrease in lesion counts than observation sides of face at weeks 2 (P < .001) and 5 (P = .02). However, there were no significant differences in patients' assessment of symptoms and in review of facial photographs for rash severity between treatment and observation sides.
Limitations: This study was not placebo controlled.
Conclusions: Pimecrolimus application did not translate into clinically meaningful benefit for patients with cetuximab-related facial rash.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaad.2009.03.046 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Management of human epidermal growth factor receptor inhibitors-related acneiform rash: A position paper based on the first Europe/USA Delphi consensus process.
J Eur Acad Dermatol Venereol
October 2024
Oncodermatology Department, Cancer University Institute, Toulouse Oncopole, Toulouse, France.
Background: There is a need for unified guidance in the management of acneiform rash induced by epidermal growth factor receptor inhibitors (EGFRi) among dermatologists.
Objective: To establish unified international guidelines for the management of acneiform rash caused by EGFR inhibitors, based on an experts' Delphi consensus.
Methods: The initiative was led by five members of the European Academy of Dermatology and Venereology Task Force 'Dermatology for Cancer Patients' who developed a questionnaire that was circulated to a group of 32 supportive oncodermatology experts in Europe, Canada, Argentina, the US States and Asia.
Multiple Pyoderma Gangrenosum Overlying AV Fistula Treated With Colchicine: A Case Report.
Can J Kidney Health Dis
October 2024
Département de Médecine, Hôpital du Sacré-Coeur de Montréal, QC, Canada.
Article Synopsis
- - Pyoderma gangrenosum (PG) is a rare condition that causes painful ulcers, which can occur after trauma like needle insertion, a phenomenon known as pathergy; this report highlights a 69-year-old woman who developed PG after hemodialysis.
- - The patient experienced painful ulcers at the site of needle insertion on her arteriovenous fistula (AVF), prompting a diagnosis of PG following a thorough evaluation that ruled out other causes.
- - Treatment involved suspending dialysis through the AVF and using medications such as prednisone, topical corticosteroids, and colchicine to manage PG; her condition improved, allowing for safe resumption of dialysis while minimizing the risk of further complications.
Pigmented actinic lichen planus: a case report.
Acta Dermatovenerol Alp Pannonica Adriat
September 2024
Clinic of Dermatology and Venereology, University Clinical Center of Serbia, Belgrade, Serbia.
Article Synopsis
- Actinic lichen planus (ALP) is a rare and photosensitive form of lichen planus, most common in younger dark-skinned females from warmer regions, with four recognized types including pigmented and classic forms.
- A case study describes a 68-year-old white man with a 9-year history of a mildly itchy hyperpigmented patch on his nose, ultimately diagnosed as pigmented ALP through histopathological analysis showing characteristic changes.
- Treatment involved topical pimecrolimus and tretinoin, effective in reducing symptoms, while emphasizing the importance of accurate diagnosis and ongoing sun protection to manage and prevent the condition.
Topical calcineurin and mammalian target of rapamycin inhibitors in inflammatory dermatoses: Current challenges and nanotechnology‑based prospects (Review).
Int J Mol Med
October 2024
Research Group of Clinical Pharmacology and Pharmacogenomics, Faculty of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, 15771 Athens, Greece.
Topical therapy remains a critical component in the management of immune‑mediated inflammatory dermatoses such as psoriasis and atopic dermatitis. In this field, macrolactam immunomodulators, including calcineurin and mammalian target of rapamycin inhibitors, can offer steroid‑free therapeutic alternatives. Despite their potential for skin‑selective treatment compared with topical corticosteroids, the physicochemical properties of these compounds, such as high lipophilicity and large molecular size, do not meet the criteria for efficient penetration into the skin, especially with conventional topical vehicles.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!